Corporate News     17-Aug-22
Natco Pharma receives USFDA tentative approval for Trabectedin for Injection
Natco Pharma announced that the U.S. Food and Drug Administration has granted tentative approval to its Abbreviated New Drug Application (ANDA) for Trabectedin for Injection (generic for Yondelis® ) for the 1mg/vial presentation.

According to industry sales data, Yondelis® generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market.

Previous News
  Natco Pharma consolidated net profit rises 241.41% in the December 2023 quarter
 ( Results - Announcements 15-Feb-24   16:17 )
  Natco Pharma announces demise of director
 ( Corporate News - 31-Jul-24   11:56 )
  Natco Pharma spurts as Q1 PAT climbs 59% YoY to Rs 668 cr
 ( Hot Pursuit - 12-Aug-24   15:13 )
  Board of Natco Pharma recommends dividend
 ( Corporate News - 12-Aug-24   15:57 )
  Natco Pharma standalone net profit rises 855.44% in the September 2023 quarter
 ( Results - Announcements 14-Nov-23   15:41 )
  Natco Pharma's Vizag unit completes USFDA inspection
 ( Corporate News - 04-Feb-23   11:07 )
  Natco Pharma
 ( Results - Analysis 28-May-24   09:50 )
  Natco Pharma consolidated net profit rises 59.05% in the June 2024 quarter
 ( Results - Announcements 12-Aug-24   15:07 )
  Natco Pharma gets USFDA nod for colorectal cancer drug
 ( Hot Pursuit - 16-Jun-23   10:22 )
  Natco Pharma clears USFDA inspection of its Pharmacovigilance compliance
 ( Corporate News - 02-Nov-23   09:05 )
  Natco Pharma Ltd spurts 4.93%, up for third straight session
 ( Hot Pursuit - 07-Jun-24   13:05 )
Other Stories
  CARE reaffirms ratings on bank facilities of PNC Infratech's subsidiaries
  05-Oct-24   10:45
  CG Power & Industrial Solutions to acquire radio frequency components biz of Renesas
  05-Oct-24   10:30
  MMP Industries to convene board meeting
  05-Oct-24   10:23
  Mahindra & Mahindra Financial Serv. to discuss results
  05-Oct-24   10:23
  Ambey Laboratories to hold board meeting
  05-Oct-24   10:23
  Aurobindo Pharma's step down subsidiary to divest its entire stake in JV 'Novagen'
  05-Oct-24   10:21
  Aurobindo Pharma's step down subsidiary to divest its entire stake in a South African JV
  05-Oct-24   10:19
  Just Dial announces board meeting date
  05-Oct-24   10:11
  L&T Finance schedules board meeting
  05-Oct-24   10:11
  Australian Premium Solar (India) announces board meeting date
  05-Oct-24   10:11
Back Top